|AHFS/Drugs.com||Professional Drug Facts|
|Chemical and physical data|
|Molar mass||602.58 g·mol−1|
|3D model (JSmol)|
As of 2020, remdesivir is being tested as a specific treatment for COVID-19. It is being used for the sickest of patients during the pandemic. It may shorten the time it takes to recover from the infection. Treatment is given by injection into a vein.
On May 1, the United States Food and Drug Administration gave doctors permission to use remdesivir on patients with COVID-19. Ordinarily, the FDA would test remdesivir first to see if it worked on patients with COVID-19, but because of the COVID-19 pandemic, they told doctors they could start using the drug before the tests were finished.
In October 2020, the National Institutes of Health told the world the results of its tests: They studied 11,000 people and found that remdesivir did not help keep COVID-19 patients alive. Gilead and some scientists said the results of the tests might not be correct.
References[change | change source]
- Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: what's next?". British Journal of Pharmacology. doi:10.1111/bph.15072. PMID 32329520.
- "Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020.
- Kolata G, Baker P, Weiland N (29 April 2020). "Remdesivir Shows Modest Benefits in Coronavirus Trial". The New York Times. Retrieved 3 May 2020.
- "Remdesivir". Drugs.com. Retrieved 30 April 2020.
- Mehta N, Mazer-Amirshahi M, Alkindi N (April 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine: S0735-6757(20)30263-1. doi:10.1016/j.ajem.2020.04.035. PMC 7158837. PMID 32336586.
- Gina Kolata; Katherine J. Wu (October 15, 2020). "Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial". New York Times. Retrieved October 21, 2020.